ImmunityBio revenue and financials
$10.29Change from previous close: +10.83%Absolute change: +$1.01
In the fiscal year ended December 2025, ImmunityBio reported revenue of $113.29M (+668.31% year over year). The net loss was $351.4M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +668.31%
- 2025 vs 2024
- Net margin
- -310.2%
- 2024: -2,804.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 502 | 383 | 504 | 362 | 469 | 152 | 143 | 182 | 250 | 317 |
| Current assets | 315 | 185 | 294 | 141 | 334 | 75.5 | 55.8 | 88.8 | 132 | 205 |
| Cash and equivalents | 88.3 | 143 | 265 | 105 | 181 | 11.4 | 75.8 | 16.8 | 23.9 | 8.1 |
| Short-term investments | 154 | 6.4 | 1.0 | 2.5 | — | — | — | — | — | — |
| Receivables | 42.6 | 2.7 | 3.2 | 1.9 | — | — | — | — | — | — |
| Inventory | 0.9 | 8.3 | 0.0 | — | — | — | — | — | — | — |
| Net property, plant and equipment | 147 | 170 | 183 | 189 | — | — | — | — | — | — |
| Goodwill | 0.9 | 0.9 | — | — | — | — | — | — | — | — |
| Other intangible assets | 13.0 | 15.0 | 17.1 | 20.0 | — | — | — | — | — | — |
| Long-term investments | — | 0.0 | 0.9 | 0.8 | 7.6 | — | — | — | — | — |
| Current liabilities | 61.8 | 54.9 | 58.3 | 501 | 369 | 24.7 | 11.6 | 27.3 | 20.9 | 12.6 |
| Accounts payable | 7.0 | 6.7 | 9.2 | 21.0 | — | — | — | — | — | — |
| Long-term debt | 477 | 462 | 682 | 241 | — | — | — | — | — | — |
| Total debt | 518 | 504 | 727 | 724 | — | — | — | — | — | — |
| Total liabilities | 1,001 | 871 | 1,090 | 812 | 713 | 34.5 | 22.4 | 35.9 | 31.6 | 24.1 |
| Total equity (incl. minority) | -500 | -488 | -586 | -450 | — | — | — | — | — | — |
| Retained earnings | -3,727 | -3,375 | -2,962 | -2,378 | — | — | — | — | — | — |
| Minority interest | 0.9 | 1.0 | 1.1 | -2.5 | — | — | — | — | — | — |